Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus KERLEDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus KERLEDEX.
HYDELTRASOL vs KERLEDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination